Murabutide

Summary

Murabutide is a synthetic analogue of muramyl dipeptide, classified as an immunomodulatory peptide. It is being investigated as an adjuvant to boost vaccine‑induced immunity and as a non‑specific immunotherapy for chronic viral infections such as HIV. The compound is administered by injection (intravenous or subcutaneous) in investigational clinical studies.

Mechanism of Action

Murabutide activates the intracellular pattern‑recognition receptor NOD2, leading to transcriptional up‑regulation of genes encoding cytokines, chemokines, receptors and signaling kinases in macrophages and dendritic cells. This triggers innate immune activation without direct endothelial inflammation, enhances antigen‑presenting cell function, and subsequently augments adaptive T‑cell and antibody responses. Synergistic effects have been reported when combined with interferon‑α.

What the Research Shows

Early work demonstrated that Murabutide improves antibody titers when co‑administered with synthetic malaria peptide vaccines, acting as a saline‑compatible adjuvant. In vitro studies showed no induction of inflammatory cytokines in endothelial cells and a capacity to suppress IgE responses after oral dosing. Clinical phase‑I/II trials in HIV‑1‑infected adults reported good tolerability, selective cytokine induction, down‑regulation of HIV coreceptors, improved lymphoproliferative responses, modest CD4⁺ T‑cell increases and, in one randomized study, a higher proportion of patients achieving undetectable viral loads after a six‑week 7 mg daily cycle. Additional investigations highlighted synergistic anti‑inflammatory cytokine production when Murabutide was combined with interferon‑α.

Reported Benefits

Preclinical data support Murabutide’s role as a potent vaccine adjuvant, enhancing antibody generation against diverse pathogens. Clinical observations suggest it can modestly restore innate immune function in HIV, improve CD4⁺ counts, and increase the proportion of patients with suppressed viral replication when added to antiretroviral therapy. The compound also appears capable of reducing IgE‑mediated responses and may synergize with cytokine therapies to boost anti‑tumor activity, although these effects remain investigational.

Limitations of the Evidence

Evidence is limited to small early‑phase studies with modest sample sizes; larger randomized trials are lacking. While one study reported a significant increase in undetectable HIV viral loads, other immunologic improvements were modest and not consistently linked to clinical outcomes. The exact contribution of NOD2 activation to observed effects is inferred rather than directly demonstrated, and no regulatory approval has been granted for any indication.

Safety Considerations

Murabutide has been generally well tolerated in the reported trials, with most adverse events being mild to moderate. Reversible grade III events occurred in a minority of participants but resolved upon discontinuation. In vitro assays indicate no direct activation of inflammatory cytokine release from endothelial cells, suggesting a favorable inflammatory safety profile. Oral administration may influence IgE levels, whereas parenteral routes do not appear to trigger such effects.

How It Is Administered

The peptide is delivered by injection, either intravenously or subcutaneously. Clinical protocols have employed daily doses of 5–9 mg administered on five consecutive days per week, typically for a six‑week cycle. Formulation details are not specified in the cited literature.

Routes of Administration

Goals & Uses

• Vaccine adjuvantVaccinologyModerate
• Cancer adjunct therapyOncologyLow
• Innate immune activationImmunostimulationModerate
• Cancer immunoadjuvantOncologyLow
• Hematopoietic stimulationHematologyModerate
• ImmunostimulationImmunomodulationModerate
• HIV immunotherapyAntiviral/immunomodulationModerate

Contraindications

• Known hypersensitivity to MDP analoguesAllergy/ImmunologyHigh
• Known hypersensitivity to muramyl dipeptide derivativesAllergyHigh
• Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
• Active systemic infection with sepsis riskInfectious DiseaseHigh
• Active autoimmune diseaseAutoimmunityModerate

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalUncommon
• Flu‑like symptomsSystemicUncommon
• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• Transient feverSystemicUncommon
• FeverSystemicCommonElevated body temperature
• Cytokine releaseImmunologicalCommon
• Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

• TNF‑α inhibitorsModerate
• Immunosuppressants (e.g., cyclosporine)Moderate
• Antiretroviral therapy (e.g., zidovudine)Low
• CorticosteroidsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric populationAgeRelative
• Pediatric patients (<12 y)AgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalClinical trial authorization only; not marketed.
• United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
• United KingdomInvestigationalNo marketing authorization; used only in research.

No regulatory approval in major jurisdictions; investigated in Phase I/II trials for cancer and infectious disease prophylaxis. Development discontinued in the early 2000s.

Evidence & Sources

• Role of muramyl peptides for the enhancement of synthetic vaccines
  Journal ArticleModerateChedid L, Audibert F, Jolivet M1986-01-01T00:00:00.000000Z
• A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients naive to antiretrovirals
  Journal ArticleModerateDe La Tribonniere X, et al.2003-01-01T00:00:00.000000Z
• Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide
  Journal ArticleModerateBahr GM, et al.1995-01-01T00:00:00.000000Z
• Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients
  Journal ArticleModerateAmiel C, et al.2002-01-01T00:00:00.000000Z
• Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
  Journal ArticleModerateBahr GM, et al.2003-01-01T00:00:00.000000Z
• Murabutide revisited: a review of its pleiotropic biological effects
  Journal ArticleModerateJakopin Ž2013-01-01T00:00:00.000000Z

Frequently Asked Questions